ArticleBiomedical optics express2026
Precise delineation of glioma margins in hyperspectral images using cross-channel spectral feature fusion.
Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperspectral imaging, as a novel non-contact, non-ionizing radiation imaging technique, can acquire abundant spectral-spatial information without damaging tissue. Addressing the critical challenge of precisely delineating boundaries during brain glioma surgery, this study proposes a new hyperspectral-assisted diagnostic and classification method for brain gliomas based on cross-channel fusion feature extraction. The method acquires tissue spectral-spatial information using hyperspectral imaging, employs a spatial-spectral fusion channel feature extraction algorithm, and designs a multi-branch feature extraction network to achieve precise discrimination between tumor and normal tissue. The network uses a multi-scale feature extraction architecture: the main branch extracts deep semantic features via composite convolutional units, while a side branch preserves the original spectral-spatial information and integrates features through residual connections, thereby substantially enhancing the model's representational capacity and robustness. The advantages of this method lie in its balance of local detail and global semantics; by complementing information across channels, it effectively strengthens feature discriminability, while also offering good generalization and interpretability. Experimental results show a classification accuracy of 97% on the validation set, a maximum accuracy of 96% on an external test set, and an average accuracy of 90%. ROC curve analysis indicates stable model performance, with AUC values up to 0.99 and an average of 0.95, significantly outperforming traditional methods. Further analysis confirms that the model effectively captures discriminative features in key spectral bands (e.g., 590-610 nm and 650-700 nm), which are highly related to hemoglobin absorption characteristics, thus providing a clear biophysical explanation for the classification results. This study not only validates the effectiveness of hyperspectral imaging combined with deep learning for brain glioma recognition, but the proposed multi-branch architecture also offers a new technical pathway for medical hyperspectral image analysis.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.